Dr. Michael Harrison is Professor Emeritus of Surgery and Pediatrics and the Director Emeritus of the Fetal Treatment Center at UCSF. He graduated cum laude from Yale University and magna cum laude from Harvard Medical School. He completed his surgical training at the Massachusetts General Hospital in Boston and his pediatric surgery fellowship at Children's Hospital of Los Angeles. He is board certified in Surgery, Pediatric Surgery, and Critical Care.
Dr. Harrison and his surgery associates confine their surgical practice exclusively to children with special interest in fetal surgery, in repair of complex birth defects involving the chest, lung, abdomen, bowel, and bladder, and surgical care of children from birth through adolescence. Dr. Harrison and his associates, The Bay Area Pediatric Surgeons, do consultations and provide surgical care at Moffitt/Long Hospitals UCSF, California Pacific Medical Center, and Kaiser Permanente, San Francisco.
Dr. Harrison has a special interest in fetal surgery which he has pioneered with his colleagues at UCSF. For the past 18 years Dr. Harrison has studied the pathophysiology and natural history of a number of life-threatening fetal abnormalities including congenital diaphragmatic hernia, congenital cystic adenomatoid malformation of the lung, sacrococcygeal teratoma, fetal obstructive uropathy, and myelomeningocele. He has developed techniques for both in-utero open fetal surgery and endoscopic surgical repair (FETENDO Fetal Surgery)of many fetal abnormalities. In addition, Dr. Harrison's team has developed in-utero stem cell transplantation to treat immunodeficiencies, enzyme deficiencies, and hemoglobinopathies. Dr. Harrison leads the multidisciplinary UCSF Fetal Treatment Center Team that has developed an international reputation for treating complex birth defects before and after birth. (Referrals can be made to 1-800-RX-FETUS.)
Dr. Harrison, his wife Gretchen, and four children have lived in San Francisco for the past 20 years.
Most recent publications from a total of 426
Swisher SL, Lin MC, Liao A, Leeflang EJ, Khan Y, Pavinatto FJ, Mann K, Naujokas A, Young D, Roy S, Harrison MR, Arias AC, Subramanian V, Maharbiz MM. Impedance sensing device enables early detection of pressure ulcers in vivo. Nat Commun. 2015; 6:6575. View in PubMed
Stover JT, Moore RA, Davis K, Harrison MR, Armstrong AJ. Reversal of PSA progression on abiraterone acetate through the administration with food in men with metastatic castration-resistant prostate cancer. Prostate Cancer Prostatic Dis. 2015 Jun; 18(2):161-6. View in PubMed
Iqbal CW, Wall J, Harrison MR. Challenges and climate of business environment and resources to support pediatric device development. Semin Pediatr Surg. 2015 Jun; 24(3):107-11. View in PubMed
Harrison MR, Emamaullee JE, Besner GE. Profiles in surgical research: Michael R. Harrison, MD, FACS. Bull Am Coll Surg. 2015 Jan; 100(1):35-40. View in PubMed
Mitchell AP, Hirsch BR, Harrison MR, Abernethy AP, George DJ. Deferred systemic therapy in patients with metastatic renal cell carcinoma. Clin Genitourin Cancer. 2015 Jun; 13(3):e159-66. View in PubMed
Motzer RJ, Rini BI, McDermott DF, Redman BG, Kuzel TM, Harrison MR, Vaishampayan UN, Drabkin HA, George S, Logan TF, Margolin KA, Plimack ER, Lambert AM, Waxman IM, Hammers HJ. Nivolumab for Metastatic Renal Cell Carcinoma: Results of a Randomized Phase II Trial. J Clin Oncol. 2015 May 1; 33(13):1430-7. View in PubMed
Li R, Beebe T, Jen N, Yu F, Takabe W, Harrison M, Cao H, Lee J, Yang H, Han P, Wang K, Shimizu H, Chen J, Lien CL, Chi NC, Hsiai TK. Shear stress-activated Wnt-angiopoietin-2 signaling recapitulates vascular repair in zebrafish embryos. Arterioscler Thromb Vasc Biol. 2014 Oct; 34(10):2268-75. View in PubMed
Hirsch BR, Harrison MR, George DJ, Walker MS, Chen C, Korytowsky B, Stepanski E, Abernethy AP. Use of "Real-World" data to describe adverse events during the treatment of metastatic renal cell carcinoma in routine clinical practice. Med Oncol. 2014 Sep; 31(9):156. View in PubMed
Miniaturizing RFID for magnamosis. Conf Proc IEEE Eng Med Biol Soc. 2014 Aug; 2014:638-41. View in PubMed
Hirsch BR, George DJ, Harrison MR. Treatment selection in metastatic renal cell carcinoma: more confusion or a path forward? Clin Adv Hematol Oncol. 2014 Mar; 12(3):163-71. View in PubMed
Please note: UCSF Profiles publications are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact CTSI for help.
"Innovation in medicine is driven by need, but also by the market," said Dr. Michael R. Harrison, the director emeritus of the Fetal Treatment Center and the director of the Pediatric Device Consortium, both at the University of California, San Francisco. "Big markets have lots of folks developing devices, but small markets like the pediatrics market don't."
Michael R. Harrison, MD, founder and director emeritus of the Fetal Treatment Center at the UCSF Benioff Children's Hospital, was recognized last week for his contributions to life-saving fetal surgery with the Ronald McDonald House Charities Medical Award of Excellence.
Surgeons at the UCSF Benioff Children's Hospital in San Francisco are using magnets to reshape the breastbones of children who suffer from Sunken Chest Syndrome. The technique is undergoing phase 3 clinical trials, but the doctors hope to prove that long term magnetic force is as effective and less painful than conventional surgery.
A new method for repairing Pectus Exacavatum using magnets and an external brace, developed by Michael Harrison, a pediatric surgeon at the University of California, San Francisco's Benioff Children's Hospital, could provide an alternative to the surgery.
UCSF has received about a million dollars since 2009. That money has supported the development of tools to treat scoliosis, kidney failure and sunken chest, among other conditions. The pectus, or sunken chest device, is in clinical trials.
The UCSF "D'Vice Squad," a group of innovators from across the Bay Area, has drawn from diverse disciplines over the last two years to develop medical devices for children.
Now the squad's hard work has been rewarded with a $1 million grant from the U.S. Food and Drug Administration (FDA) to expand its work over the next two years.
For years, surgeons have been seeking ways of operating on babies in the womb, reasoning that medical abnormalities are easier to address while the fetus is still developing. Now, for the first time, a large clinical trial has shown that fetal surgery can also benefit infants with non life-threatening conditions. The eight-year study reported in the New England Journal of Medicine, found that babies born with myelomeningocele, the most common form of spina bifida, a debilitating spinal [...]
UCSF announces the formation of the Institute for Fetal and
Neonatal Health symposium brings together clinicians and basic
scientists involved in different aspects of development and fetal
Stopping curvature of the spine in kids usually requires a series of painful operations to implant rods and screws to adjust the spine. Even then, the results are often less than perfect. However, a medical team at UCSF has developed a technique using magnets that promises to do away with so many surgeries.
In our efforts to establish a distinguished professorship in honor of Michael R. Harrison, M.D, an extremely generous donor has called for a challenge. The anonymous donor has pledged a gift of $500,000 in the form of a match. Our goal must be met by Dec 31, 2009.
Michael Harrison M.D., a renowned pioneer in fetal and pediatric surgery, Professor Emeritus of Surgery and Pediatrics, and Director Emeritus of the Fetal Treatment Center at UCSF, has been elected to the prestigious Institute of Medicine (IOM), one of the U.S. National Academies. Membership in the IOM reflects "the height of professional achievement and commitment to service" and is reserved for those at the pinnacle of their field.